Compared with patients receiving hormone therapy alone, patients were nine times more likely to havelittle to no cancer remaining in the prostate after s...
As artificial intelligence becomes increasingly embedded in healthcare research, the ability to generate reliable, transparent, and regulatory-grade eviden...
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering,...
ProBioGen announced the launch of AGE1.CR.ReX®, its next-generation avian designer cell line for stable, high-titer poxvirus production and rapi...
Approval granted by South Korea's Ministry of Food and Drug Safety (MFDS) Eptinezumab is an anti-calcitonin gene-related peptide (CGRP) monoclonal ant...
Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obef...
Ebola IC50 (0.125μM)—Strong inhibition at less than half the concentration of the clinically-tested COVID-19 (0.28μM). ...
Head-to-Head Study Highlights Rocbrutinib as the World's First Fourth-Generation Dual Covalent and Non-Covalent BTK Inhibitor Designed to Overcome Resist...
G-Link enables targeted in vivo delivery and streamlines ex vivo workflows without lentiviral vector reengineering G-Link supports multiple delivery...
EpiCypher® and New England Biolabs® (NEB®) announced an expanded strategic partnership to co-develop next-generation tools for epigenom...
SERB Pharmaceuticals (“SERB”) and Hansa Biopharma AB (“Hansa”) (Nasdaq Stockholm: HNSA) announced that they have entered into an ...
Hu-mAtrIx™-Enabled Next-Generation ACVR2A/2B-Targeting Antibody Demonstrates Potential to Become a Bes...
Positive Phase III readout of National Cancer Institute sponsored SWOG S1602 randomized clinical trial demonstrating non-inferior efficacy of the Tok...
Clearance Recognises CellDx-Tissue's Dual-Analyte DNA and RNA Workflow Across 517 Cancer-Associated Genes, with ALK, RET and ROS1 Fusion Calls on RNA-Lev...
© 2026 Biopharma Boardroom. All Rights Reserved.
